61,749 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by World Investment Advisors LLC

World Investment Advisors LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 61,749 shares of the medical research company's stock, valued at approximately $14,633,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter worth about $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the 3rd quarter valued at approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA in the 2nd quarter worth approximately $29,000. International Assets Investment Management LLC purchased a new position in IQVIA during the 2nd quarter worth approximately $32,000. Finally, Avior Wealth Management LLC raised its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.3 %

Shares of IQVIA stock traded down $0.70 during midday trading on Thursday, reaching $200.37. 1,143,937 shares of the company's stock traded hands, compared to its average volume of 1,186,217. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company's 50 day simple moving average is $213.40 and its 200 day simple moving average is $224.61. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.37 billion, a price-to-earnings ratio of 26.29, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49.

Wall Street Analyst Weigh In

IQV has been the subject of several recent analyst reports. Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. BTIG Research dropped their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $257.60.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.